Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01283048 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma
A Phase 1 study, sponsored by Toni Choueiri, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01283048 is a Phase 1 study that has completed, run by Toni Choueiri, MD. The registered enrollment target is 32 participants.
The verdict
NCT01283048, a Phase 1 study, has completed, sponsored by Toni Choueiri, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
BKM-120 is a drug that may slow the growth of cancer cells. This drug has been used in laboratory experiments and information from those research studies suggests that this drug may help to slow the growth of renal cancer cells. In this research study, the investigators are testing the safety to BKM-120 at different dose levels. The investigators will also be studying how well tolerated BKM-120 is, and how effective BKM-120 can be in the treatment of kidney cancer.
Interventions
- DRUG BKM-120 Bevacizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2011-09 |
| Est. Completion | 2016-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01283048
The ClinicalTrials.gov registry entry for NCT01283048 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Toni Choueiri, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BKM-120 Bevacizumab is the first listed.
NCT01283048 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01283048 about?
NCT01283048 is a clinical study titled "Bevacizumab and BKM-120 in Patients With Metastatic Renal Cell Carcinoma". BKM-120 is a drug that may slow the growth of cancer cells. This drug has been used in laboratory experiments and information from those research studies suggests that this drug may help to slow the growth of renal cancer cells. In this research study, the investigators are testing the safety to BKM...
What is the current status of trial NCT01283048?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2011-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01283048?
The interventions under investigation include: BKM-120 Bevacizumab (DRUG).
Who is sponsoring clinical trial NCT01283048?
This trial is sponsored by Toni Choueiri, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.